https://www.selleckchem.com/pr....oducts/bardoxolone.h
8 vs. 1.9 months, p 0.001, and 37.8 vs. 8.1 months, p 0.001, respectively). Multivariate analysis associated with PFS and OS indicated that the development of irAEs was an independent favorable prognostic factor. Among the patients developing irAEs, the responder group had a significantly higher incidence of multiple irAEs than the non-responder group (41.7 vs. 0.0%, p = 0.009). Our findings revealed that the development of irAEs was associated with clinical benefits in NSCLC patients who received immunotherapy. In particu
Like
Comment
Share
